A Maturing Amgen Focuses On Capital Allocation, Late-Stage Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Even as it reaffirms its big long-term bet on R&D, Amgen appeases investors with tweaks to its R&D organization and expansion of its share buyback program.